Media.Player

Lipopolysaccharide Antagonist Molecule AM-12

IP Title

SACCHARIDE CONJUGATES

Detailed Technology Description

None

Application Date

Oct 18, 2013

Application No.

9,120,838

Others

*Abstract

Novel Compounds with Potential to Treat Septic Shock and Alzheimer’s (UM No. 11UMS002)Septicemia is a serious world-wide health problem associated with mortality rates of 40-60%. It is well established that septic shock is initiated by introduction of bacterial endotoxin (or lipopolysaccharide, LPS) into the blood stream. LPS is composed of three structural regions. One of these, the Lipid-A region, consists of a polyacylated glucosamine disaccharide and is largely responsible for the toxic activity. The results of recent studies suggest that the ensuing pro-inflammatory response to LPS is by far more dangerous than the mere presence of LPS in circulation.Currently, some synthetic Lipid-A analogs that have been developed do have antagonistic/agonistic properties, but most have limited shelf life and are cumbersome to synthesize and handle. Researchers at the University of Missouri-St. Louis (Demchenko et al) have discovered a new and simplified series of Lipid-A analogs to block the pro-inflammatory response to LPS. This work has potential commercial application in research investigations to elucidate LPS signaling pathways, as a therapeutic for treatment of septic shock, and as a drug to treat the inflammatory component of Alzheimer’s disease. Synthesis is very simple and scalable.Intellectual Property: US Patent No. 9,120,838Contact: Tamara Wilgers, DirectorTechnology Commercialization & Economic DevelopmentUniversity of Missouri-St. Louis314-516-6884wilgerst@umsl.edu

*IP Issue Date

Sep 1, 2015

*Principal Investigator

Name: Alexei Demchenko

Department:

Name: Michael Nichols

Department:

Name: Geeta Paranjape

Department:

Name: Sophon Kaeothip

Department:

Name: Shana Terrill

Department:

Country/Region

USA